Synagis and Intestinal obstruction - a phase IV clinical study of FDA data

Summary:

Intestinal obstruction is reported as a side effect among people who take Synagis (palivizumab), especially for people who are male, 0-1 old, have been taking the drug for < 1 month also take Aminophyllin, and have Premature baby.

The phase IV clinical study analyzes which people have Intestinal obstruction when taking Synagis. It is created by eHealthMe based on reports of 19,108 people who have side effects when taking Synagis from the FDA, and is updated regularly.

What is Synagis?

Synagis has active ingredients of palivizumab. eHealthMe is studying from 19,114 Synagis users. Check the latest studies of Synagis.

What is Intestinal obstruction?

Intestinal obstruction is found to be associated with 1,883 drugs and 2,619 conditions by eHealthMe. Check the latest studies of Intestinal obstruction.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

19,108 people reported to have side effects when taking Synagis.
Among them, 31 people (0.16%) have Intestinal obstruction.

Could Synagis cause Intestinal obstruction?

Among these 31 people:

How long have people been on Synagis when they have Intestinal obstruction? *

What is the gender of people who have Intestinal obstruction when taking Synagis? *

female: 42.31 %
male: 57.69 %

What is the age of people who have Intestinal obstruction when taking Synagis? *

What are other drugs people take besides Synagis? *

What are other side effects people have besides Intestinal obstruction? *

Dehydration (dryness resulting from the removal of water): 5 people, 16.13%
Viral Infection: 5 people, 16.13%
Nausea And Vomiting: 5 people, 16.13%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 12.90%
Weight Decreased: 3 people, 9.68%
Respiratory Distress (difficulty in breathing): 3 people, 9.68%
Food Intolerance (inability to have food): 3 people, 9.68%
Gastroenteritis (inflammation of stomach and intestine): 3 people, 9.68%
Hernia (hernia happens when part of an internal organ or tissue bulges through a weak area of muscle): 3 people, 9.68%
Abdominal Adhesions (inflammation of abdomen): 3 people, 9.68%

What are the existing conditions these people have? *

Premature Baby: 6 people, 19.35%
Respiratory Syncytial Virus Infection (viral disease of respiratory system): 2 people, 6.45%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 3.23%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 1 person, 3.23%
Chronic Respiratory Failure: 1 person, 3.23%
Chronic Respiratory Disease: 1 person, 3.23%
Bronchopulmonary Dysplasia (chronic lung disorder in infants - enlargement of an organ or tissue by the proliferation of cells of an abnormal type): 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Synagis and have Intestinal obstruction?

- Check whether Intestinal obstruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Synagis:

Synagis (19,114 reports)

Browse all side effects of Synagis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intestinal obstruction:

Intestinal obstruction (1,883 drugs)

Browse all the conditions that are associated with Intestinal obstruction:

Intestinal obstruction (2,619 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on palivizumab (the active ingredients of Synagis) and Synagis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.